Utah Team Finds Novel Strategy to Combat Tuberculosis

OREM, Utah – February 03, 2026 – An international team of scientists led by a researcher at Utah Valley University has developed a powerful new class of compounds that represents a paradigm shift in the fight against tuberculosis (TB), the world’s single deadliest infectious disease. The discovery targets the bacterium's defense mechanisms rather than killing it outright, offering a promising new path to overcome the growing threat of antibiotic resistance.

The research, led by Nathan Goldfarb, Ph.D., an associate professor in UVU’s College of Science, was recently published in the European Journal of Medicinal Chemistry Reports. It details the creation of small molecules that effectively neutralize Mycobacterium tuberculosis, preventing it from surviving inside the very immune cells meant to destroy it.

A Global Scourge in Need of New Weapons

Tuberculosis remains a formidable global health crisis. According to the World Health Organization, an estimated 10.8 million people fell ill with TB in 2023, and 1.25 million died from the disease. It is a leading cause of death worldwide and a major driver of fatalities linked to antimicrobial resistance. While present in all countries, the burden falls heaviest on the regions of South-East Asia and Africa.

The standard treatment for TB is a grueling, months-long regimen of multiple antibiotics. This lengthy and complex process contributes to non-adherence, which in turn fuels the development of multidrug-resistant TB (MDR-TB). MDR-TB is a public health emergency, requiring treatments that can last up to two years with toxic drugs that have debilitating side effects and offer lower chances of a cure. With the pipeline for new antibiotics considered critically poor, innovative approaches are desperately needed.

This new research offers exactly that—a fundamentally different strategy. Instead of a frontal assault on the bacterium, the Utah-led team has developed a method of sabotage.

Rewriting the Rules of Engagement

The breakthrough centers on a protein called Hip1, a virulence factor that Mycobacterium tuberculosis uses as a key weapon. Hip1 acts like a shield, allowing the bacteria to survive and multiply within macrophages, the human body's frontline immune cells. It essentially helps the pathogen hide from the immune system and tolerate antibiotic treatment.

Using rational drug design and X-ray crystallography, Dr. Goldfarb’s team engineered two small molecules that bind to the Hip1 enzyme and disable it. By inhibiting this protein, the compounds effectively disarm the bacteria.

“This work focuses on disarming the bacteria rather than killing it outright,” said Goldfarb, the study's senior author. “By targeting a virulence factor that helps TB evade the immune system, we may be able to improve treatment outcomes while reducing the risk of antibiotic resistance.”

The results were significant. In laboratory tests, the new compounds dramatically reduced the survival of TB bacteria inside infected macrophages without causing harm to the host cells. One compound was particularly effective, showing a strong and sustained reduction in the bacterial burden over time while exhibiting low toxicity. This approach avoids the intense selective pressure that traditional antibiotics create, which forces bacteria to either die or evolve resistance. By simply neutralizing the pathogen's defenses, it leaves the weakened bacteria vulnerable to the host's own immune system.

From Classroom to Global Breakthrough

This major scientific advance originated not in a world-renowned research institute, but at Utah Valley University, an institution that prides itself on its focus on undergraduate education. The project demonstrates that impactful, globally relevant research can thrive outside of traditional R1 universities.

Dr. Goldfarb, whose background includes research into HIV, malaria, and Alzheimer's, has made it a mission to involve students in high-level scientific inquiry. This project provided meaningful research opportunities for UVU students in biochemistry, medicinal chemistry, and infectious disease, allowing them to contribute to a potential solution for a global health crisis.

“This is an excellent example of how undergraduate-focused institutions like UVU can contribute to globally relevant scientific discoveries,” Goldfarb noted.

The discovery was not a solo effort. It reflects a broad, multi-institutional collaboration with researchers at Johns Hopkins University, the University of Adelaide in Australia, Utah State University, and California State University, Fresno. This network of expertise was crucial for the complex work of designing, synthesizing, and testing the novel compounds.

The Long Road from Lab to Clinic

While the discovery is a major milestone, the journey from a promising compound in the lab to an approved treatment in the clinic is long and challenging. This research lays the essential groundwork for the next phase: preclinical trials. The team's future work will involve optimizing the compounds to improve their potency and safety, as well as testing them in animal models.

A key area of investigation will be how these new molecules perform in combination with existing TB drugs. A compound that weakens the bacteria’s defenses could make it far more susceptible to traditional antibiotics, potentially allowing for shorter treatment durations, lower dosages, and a more effective assault on drug-resistant strains.

Navigating the drug development pipeline for TB is notoriously difficult. The current pipeline has only 28 drugs in clinical trials, a small number given the scale of the disease. The high cost of development, the complexity of clinical trials, and the economic challenges of bringing a TB drug to market have all hampered progress. However, therapies with novel mechanisms of action like this one are exactly what public health experts say is needed to reinvigorate the pipeline. This new disarming strategy represents a critical step forward in the global effort to finally turn the tide against this ancient and deadly disease.